Medplus Health Services Ltd

- The company currently has no debt apart from timing mode of depreciation. - The management indicated that operating cash flows are expected to turn positive and generate surplus cash in the next 2-3 years. - Planned investment for store expansion is around INR 200-220 crores annually, with 600-800 stores expected to be added per year. - Future growth funding will primarily come from operating cash flows and leveraging working capital credit lines as needed, rather than fresh debt or equity fundraising. - No explicit mention of new equity or debt fundraising plans in the current fiscal or near future was provided. - The focus is on reaching cash flow stability and self-funding growth through operational earnings and internal accruals.

- The company is currently in a growth phase, investing around INR 200-220 crores per year on store expansion, with about INR 25-30 lakhs invested per store. - They plan to add approximately 600 new stores in fiscal year 2025. - Capex for diagnostics within Hyderabad will involve only maintenance-type investments (e.g., ultrasound machines), with no large-scale capital expenditures planned. - Overall, operating cash flows are expected to remain negative during the growth phase due to ongoing investments. - Management expects to generate surplus operating free cash flow in 2-3 years as store base matures and EBITDA grows. - Future cash flow and capex needs will be managed through credit lines as necessary. - The focus remains on expanding the pharmacy network, especially in Tier 2 cities and beyond, with strategic investments supporting store additions and private label brand growth.

- The company expects GMV (Gross Merchandising Value) growth of around 27.4% year-on-year, indicating strong volume growth. - In Tamil Nadu, GMV growth exceeds 16% where focused advertising has been done. - Private label GMV has grown significantly from 8.1% last year to 13.7% currently, supporting revenue growth. - Store additions are expected to continue at around 600 stores per year, with growth focus in Tier 2 cities and beyond. - Mature stores (24-36 months) typically grow at a same-store sales growth rate of approximately 10%, driven by pharma inflation plus category expansion. - The share of revenue from Tier 2 markets has increased to 35%, up from 33% last year, contributing to diversified growth. - The company targets improving pharmacy operating EBITDA margins alongside volume growth driven by private label expansion and operational leverage.

- MedPlus expects significant growth in EBITDA going forward, currently at INR 170 crores. - Operating EBITDA margin for pharmacy retail was about 4% in Q4 FY24, expected to grow to 4.5%-5% in FY25. - Margin improvement drivers include store maturity, higher EBITDA in smaller towns, and scaling of private label products. - Same-store sales growth anticipated around 10%, factoring pharma inflation and new category additions. - Cash generation expected to improve with store base growth and lower capex per store (~INR 25-30 lakh), projecting positive operating free cash flow within 2-3 years. - Potential margin upside if margins improve by 1-1.5% due to operational leverage and private label expansion. - The company targets adding roughly 600-800 stores annually, with investment around INR 200-220 crores per year. - FY25 outlook suggests gradual margin improvement and cash flow positivity as stores mature and efficiencies scale.

The provided transcript from the MedPlus Health Services Limited Q4 FY'24 earnings call does not explicitly mention details related to the company's current or expected order book or pending orders. The discussion primarily focuses on: - Private label sales growth and customer mix. - Store network expansion and store-level performance. - Discounting trends in the pharma retail market. - Diagnostic business updates. - Financial metrics such as revenue, EBITDA, working capital, and tax rates. No specific data or commentary on order book or pending orders is addressed in the transcript.